CNS Pharmaceuticals, Inc. Interest Expense Nonoperating
CNS Pharmaceuticals, Inc. (CNSP) reported Interest Expense Nonoperating of $4.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-12
- CNS Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $4.00K, a 0.00% change year-over-year.
- CNS Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $6.11K, a 1.56% decline year-over-year.
- CNS Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $2.72K, a 1.91% decline year-over-year.
- CNS Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $2.12K, a 6.29% decline year-over-year.
- CNS Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2025 was $15.23K, a 5.52% decline from fiscal 2024.
- CNS Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2024 was $16.12K, a 16.77% increase from fiscal 2023.
- CNS Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2023 was $13.80K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 3 month as first filed | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 6 month as first filed | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4.00K 10-Q · filed 2026-08-12 | $10.00K 10-Q · filed 2026-08-12 | $12.83K derived: sum of 3 quarters · filed 2026-08-12 | $14.95K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $6.11K 10-Q · filed 2026-05-14 | $8.83K derived: sum of 2 quarters · filed 2026-05-14 | $10.95K derived: sum of 3 quarters · filed 2026-05-14 | $14.95K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | $2.72K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $4.84K derived: sum of 2 quarters · filed 2026-03-31 | $8.84K derived: sum of 3 quarters · filed 2026-08-12 | $15.23K 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $2.12K 10-Q · filed 2025-11-14 | $6.12K derived: sum of 2 quarters · filed 2026-08-12 | $12.51K 10-Q · filed 2025-11-14 | $15.10K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $4.00K 10-Q · filed 2026-08-12 | $4.18K 10-Q · filed 2025-08-14 | $10.00K 10-Q · filed 2026-08-12 | $10.39K 10-Q · filed 2025-08-14 | $12.98K derived: sum of 3 quarters · filed 2026-08-12 | $15.24K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $6.21K 10-Q · filed 2026-05-14 | $8.98K derived: sum of 2 quarters · filed 2026-05-14 | $11.24K derived: sum of 3 quarters · filed 2026-05-14 | $15.70K derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $2.77K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $5.03K derived: sum of 2 quarters · filed 2026-03-31 | $9.49K derived: sum of 3 quarters · filed 2026-03-31 | $16.12K 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $2.26K 10-Q · filed 2025-11-14 | $6.72K derived: sum of 2 quarters · filed 2025-11-14 | $13.35K 10-Q · filed 2025-11-14 | $16.23K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $4.46K 10-Q · filed 2025-08-14 | $11.09K 10-Q · filed 2025-08-14 | $13.97K derived: sum of 3 quarters · filed 2025-08-14 | $15.81K derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $6.63K 10-Q · filed 2025-05-15 | $9.51K derived: sum of 2 quarters · filed 2025-05-15 | $11.34K derived: sum of 3 quarters · filed 2025-05-15 | $14.99K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $2.88K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $4.72K derived: sum of 2 quarters · filed 2025-03-31 | $8.37K derived: sum of 3 quarters · filed 2025-03-31 | $13.80K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $1.84K 10-Q · filed 2024-11-14 | $5.49K derived: sum of 2 quarters · filed 2024-11-14 | $10.92K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $3.65K 10-Q · filed 2024-08-14 | $9.09K 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |